Industry: Pharma tech

Pharmaceutical technology VC funding

Startups that build software for trials, regulatory filings, drug plants and pharma sales are raising again, often around AI. We help pharma tech founders show investors the contracts, renewals and validation behind the product.

  • Funding data and investor types for trial, regulatory and pharma software
  • Decks and models built on drugmaker contracts, validation and renewals
  • Waveup prepares investor materials for pharma technology companies: $3B+ raised for 600+ startups since 2014

In short

What is pharmaceutical technology VC funding?

Pharmaceutical technology VC funding is venture money for companies that sell software and data to drugmakers. It covers trial platforms, regulatory and safety software, commercial tools and plant systems. Clinical trial tech raised $1.04B in 2026 to early November, by Tracxn's count. This page is for founders building these tools, not for drugmakers buying them.

Who it's for
Companies building trial, regulatory, commercial and manufacturing software for drugmakers, pre-seed to Series D+
What we build
Investor deck, financial model, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 6 November 2026. Sources are under each section.

Are investors funding pharma tech again in 2026?

Yes. By early November 2026, clinical trial tech had raised more than in 2024 and 2025 combined, by Tracxn's count.

The opportunity

Drugmakers want faster, cheaper trials, and regulators are making room for new tools.

  • New good clinical practice rules, in force in the EU, favour risk-based, fit-for-purpose trials
  • FDA guidance now covers trial visits by telehealth, at home or with local doctors
  • The FDA has set out guiding principles for good AI practice in drug development

The problem

Funding for trial technology fell for four years after 2021. Tracxn counts $365M raised in 2025.

Market size

How big is pharma software, and what is moving it?

Veeva makes cloud software for the life sciences industry. It earned $3.20B in fiscal 2026, the year to 31 January. Four shifts shape what drugmakers buy next:

  • Trial volume: nearly 32,000 interventional trials were first posted on ClinicalTrials.gov in 2025, by our count
  • One EU portal: since 31 January 2025, every running EU trial must be recorded in CTIS
  • AI in filings: the FDA's drug centre has seen more than 500 submissions with AI components, 2016 to 2023
  • US plants: only 11% of active-ingredient makers for FDA-approved drugs are American, and FDA's PreCheck helps new plants prepare
Veeva's total revenues: $690.6M in fiscal 2018 and $3.20B in fiscal 2026.

Pharma tech in 2026, in six numbers

610,756

studies registered on ClinicalTrials.gov on 6 November 2026

30

European countries a sponsor can apply to through CTIS, the EU trials portal

1,552

customers served by Veeva at the end of January 2026

60%

of Veeva's subscription revenue came from North America in fiscal 2026

~70%

of FDA and EMA novel drug approvals in the past decade drew on Clario's technology, Thermo Fisher says

>50%

of medicines distributed in the US are made overseas, the FDA said in 2025

Venture capital

Is venture money returning to clinical trial tech?

Funding for clinical trial technology peaked in 2021, then shrank each year to 2025. By early November 2026 it had passed $1B again, by Tracxn's count.

Clinical trial tech funding worldwide: $1.81B in 2021, $365M in 2025 and $1.04B in 2026 to early November.
$578M

of equity raised by clinical trial tech companies in 2026 to October, up from $205M a year earlier

$8.875B

paid in cash by Thermo Fisher for Clario, a clinical trial data company, at closing in March 2026

$52M

Series A for Biorce, a Barcelona startup that uses AI to plan trials, in February 2026

Who invests in pharma tech startups?

Venture arms of companies in the drug business, B2B software VCs and private equity. Five examples follow; for more names, see our lists of healthcare venture capital firms and B2B SaaS venture capital firms.

Investor
Type and base
Pharma tech companies backed
Stage or cheque
McKesson Ventures
Venture arm of McKesson; San Francisco
Saama, Koneksa, Bluenote
Venture and growth stage
Labcorp Venture Fund
Venture fund of Labcorp; $300M+ deployed since 2012
IgniteData, Acclinate, TrakCel
Not stated
Debiopharm Innovation Fund
Venture arm of Debiopharm, a Swiss biopharma company; $150M fund
Stitch, Octozi, Risklick
Under $1M at pre-seed or seed; $3M–5M at Series A
Emergence Capital
B2B software VC, San Francisco
Veeva (partnered in 2008, now public)
Early stage
GI Partners
Private investment firm; offices in San Francisco, New York, London and four more
Clinical Ink, eClinical Solutions
Not stated; $49B+ raised since 2001

Investor database

Pharma investors in our database

The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by pharma investments

  • Investments by industry

    • Healthtech & Wellness48%
    • Biotech24%
    • Pharma21%
    Rounds
    Series ASeries BSeries C+
    Average cheque
    $500K–$1M$1M–$3M$3M–$10M$10M–$50M
    Based in
    New York, United States
    Invests in
    East Asia, USA

    704 investments in total, 21 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness42%
    • Biotech26%
    • Pharma18%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $100K–$500K$500K–$1M
    Based in
    Cambridge, United States
    Invests in
    Southeast Asia, USA

    613 investments in total, 17 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness45%
    • Biotech30%
    • Pharma19%
    Rounds
    Series ASeries BSeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Menlo Park, United States
    Invests in
    Europe, USA, Canada

    382 investments in total, 13 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Software & Apps36%
    • AI & Deep Tech17%
    • Healthtech & Wellness16%
    • Pharma3%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $3M–$10MOver $50M$10M–$50M
    Based in
    Boston, United States

    315 investments in total, 6 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Software & Apps29%
    • Healthtech & Wellness19%
    • AI & Deep Tech7%
    • Pharma5%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $500K–$1M$1M–$3M$3M–$10M$10M–$50M
    Based in
    Menlo Park, United States
    Invests in
    USA

    2225 investments in total, 5 tagged Pharma.Open the full fund profile

From our investor database.

What do investors question first in pharma tech?

Our Fundraising 2025 study asked 56 VCs why they pass. Revenue growth, unit economics, burn and missed milestones came first, then defensibility and crowded categories. Pharma tech founders face four questions of their own.

Few buyers, slow deals

Pharma software sells to a short list of large drugmakers. Veeva's top 10 customers brought in 28% of its revenue in fiscal 2026.

What investors ask

  • How many large drugmakers have signed, and how long did each contract take?

What your deck shows

  • Signed contracts, renewals and sales cycle length by customer
  • A route to mid-size biotechs and CROs too

Trials beyond the site

Science 37, a Nasdaq-listed company that took trials beyond traditional sites, agreed in January 2024 to sell to eMed. The deal valued its equity at about $38 million.

What investors ask

  • Will sponsors pay for this on every study, or only for some trials?

What your deck shows

  • Revenue per study and how many sponsors come back
  • Gross margin after home visits, devices and staff

AI a regulator can trust

In January 2025 the FDA drafted guidance on using AI to support regulatory decisions on drugs. Sponsors now ask how a model's output will hold up in review.

What investors ask

  • Can your output go into a regulatory submission, and has it already?

What your deck shows

  • Validation records and an audit trail for each model
  • Studies or filings where sponsors used your output

Suites that add the same feature

Veeva is adding AI agents to its own applications. Its subscription revenue grew 17% in fiscal 2026.

What investors ask

  • What stops Veeva, IQVIA or Medidata from adding this to their suites?

What your deck shows

  • A task the suites leave undone, with customer proof
  • Connectors that let you sell alongside them

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

    From $6,000

    What your product saves a drugmaker in time, cost or risk, with proof.

    From $3,000

    Contract value, set-up fees, renewals and AI costs, month by month.

    From $5,000

    A range checked against pharma software deals and listed peers.

    Health VCs, venture arms of pharma and lab groups, and growth funds.

    Validation files, security reviews and customer contracts, ready to check.

    For a sale to a lab group, a CRO, a software suite or a buyout fund.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Health
11%
of our projects on record are in healthcare and life sciences

Pharmaceutical technology VC funding FAQ

What is pharma tech?
Pharma tech is software and data sold to drugmakers, contract research organisations (CROs) and trial sites. It supports clinical trials, regulatory filings, drug safety, sales and medical teams, and drug plants. Drug discovery belongs to biotech, and drugmakers themselves to pharmaceuticals. Veeva, which makes cloud software for life sciences, earned $3.20B in fiscal 2026.
How do pharma tech startups get funding?
How much venture capital goes into clinical trial tech in 2026?
What do investors look for in a pharma tech startup?
Who buys pharma tech companies?
How much does help with a pharma tech raise cost?

Raising for a pharma tech company?

Tell us who uses your software at drugmakers and what they pay. We'll show you what investors will check before a term sheet.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?